Compounds > terbutaline
Page last updated: 2024-11-04

terbutaline and Diabetes Mellitus, Type 1

terbutaline has been researched along with Diabetes Mellitus, Type 1 in 12 studies

Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.
terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.

Diabetes Mellitus, Type 1: A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.

Research Excerpts

ExcerptRelevanceReference
"0 mg of the beta(2)-adrenergic agonist terbutaline prevents nocturnal hypoglycemia but causes morning hyperglycemia in type 1 diabetes."9.13Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes. ( Arbelaez, AM; Breckenridge, SM; Cooperberg, BA; Cryer, PE, 2008)
"To test the hypothesis that because of sustained glycemic actions, bedtime administration of the glucagon-releasing amino acid alanine or the epinephrine-simulating beta2-adrenergic agonist terbutaline more effectively prevents nocturnal hypoglycemia than a conventional bedtime snack, we studied 15 patients with IDDM."9.08Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM. ( Cryer, PE; Saleh, TY, 1997)
"To test the hypothesis that, in contrast to administration of glucose or glucagon, administration of the amino acid Ala or of the beta 2-adrenergic agonist terbutaline produces sustained glucose recovery from hypoglycemia."9.07Alanine and terbutaline in treatment of hypoglycemia in IDDM. ( Cryer, PE; Wiethop, BV, 1993)
" We describe diabetic ketoacidosis and transient severe insulin resistance in a woman with diabetes who was treated with subcutaneous terbutaline infusion."7.68Diabetic ketoacidosis and insulin resistance with subcutaneous terbutaline infusion: a case report. ( Lorber, DL; Nerenberg, A; Tibaldi, JM, 1990)
"To determine the effects of reducing overnight basal insulin or a bedtime dose of terbutaline on nocturnal blood glucose (BG) nadir and hypoglycemia after exercise in children with type 1 diabetes mellitus."5.14Preventing post-exercise nocturnal hypoglycemia in children with type 1 diabetes. ( Chase, HP; Cobry, E; Fiallo-Scharer, R; McFann, K; Messer, L; Taplin, CE, 2010)
"0 mg of the beta(2)-adrenergic agonist terbutaline prevents nocturnal hypoglycemia but causes morning hyperglycemia in type 1 diabetes."5.13Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes. ( Arbelaez, AM; Breckenridge, SM; Cooperberg, BA; Cryer, PE, 2008)
"To test the hypothesis that because of sustained glycemic actions, bedtime administration of the glucagon-releasing amino acid alanine or the epinephrine-simulating beta2-adrenergic agonist terbutaline more effectively prevents nocturnal hypoglycemia than a conventional bedtime snack, we studied 15 patients with IDDM."5.08Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM. ( Cryer, PE; Saleh, TY, 1997)
"To test the hypothesis that, in contrast to administration of glucose or glucagon, administration of the amino acid Ala or of the beta 2-adrenergic agonist terbutaline produces sustained glucose recovery from hypoglycemia."5.07Alanine and terbutaline in treatment of hypoglycemia in IDDM. ( Cryer, PE; Wiethop, BV, 1993)
" We describe diabetic ketoacidosis and transient severe insulin resistance in a woman with diabetes who was treated with subcutaneous terbutaline infusion."3.68Diabetic ketoacidosis and insulin resistance with subcutaneous terbutaline infusion: a case report. ( Lorber, DL; Nerenberg, A; Tibaldi, JM, 1990)
"Nocturnal hypoglycemia is common in aggressively treated type 1 diabetes."2.72Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. ( Arbelaez, AM; Breckenridge, SM; Cryer, PE; Raju, B, 2006)
"In patients with IDDM it raised glucagon (P = 0."2.67Glycemic actions of alanine and terbutaline in IDDM. ( Cryer, PE; Wiethop, BV, 1993)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19901 (8.33)18.7374
1990's6 (50.00)18.2507
2000's3 (25.00)29.6817
2010's2 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cooperberg, BA1
Breckenridge, SM2
Arbelaez, AM2
Cryer, PE5
Taplin, CE1
Cobry, E1
Messer, L1
McFann, K1
Chase, HP1
Fiallo-Scharer, R1
Nosek, L1
Cardot, JM1
Owens, DR1
Ibarra, P1
Bagate, K1
Vergnault, G1
Kaiser, K1
Fischer, A1
Heise, T1
Enoksson, S1
Caprio, SK1
Rife, F1
Shulman, GI1
Tamborlane, WV1
Sherwin, RS1
Raju, B1
Wiethop, BV2
Lorber, D1
Krim, E1
Saleh, TY1
Hagström-Toft, E1
Tibaldi, JM1
Lorber, DL1
Nerenberg, A1
Krone, W1
Naegele, H1
Behnke, B1
Greten, H1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effect of Using Terbutaline or a Reduction in Basal Insulin Infusion as a Therapeutic Agent to Prevent Delayed Nocturnal Hypoglycemia in Children and Adolescents With Type 1 Diabetes[NCT00974051]16 participants (Actual)Interventional2008-03-31Completed
The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes[NCT02660242]Phase 216 participants (Actual)Interventional2016-01-31Completed
Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes[NCT02411578]Phase 226 participants (Actual)Interventional2015-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Blood Glucose Nadir

BG nadir overnight after intervention (NCT00974051)
Timeframe: overnight hours

Interventionmg/dl (Mean)
Control Arm128
Terbutaline Arm189
20% Basal Reduction Arm162

Percent of Nighttime Glucose Levels <70

(NCT00974051)
Timeframe: 10:00pm to 6:00am

Interventionpercentage of nighttime glucose values (Number)
Control Arm1.7
Terbutaline Arm0
20% Basal Reduction Arm0.3

Percent of Nighttime Glucose Levels <80

(NCT00974051)
Timeframe: 9:00pm to 6:00am

Interventionpercentage of overnight glucose levels (Number)
Control Arm6.6
Terbutaline Arm0
20% Basal Reduction Arm4.9

Percent of Nighttime Glucose Levels >250 mg/dl

(NCT00974051)
Timeframe: 10:00pm to 6:00am

Interventionpercentage of overnght glucose values (Number)
Control Arm30.2
Terbutaline Arm63.5
20% Basal Reduction Arm41.7

CGM Metrics During Late Recovery - Coefficient of Variation

Comparison of the coefficient of variation from CGM between the exercise strategies. (NCT02660242)
Timeframe: 90 min after the standard meal until 1200 noon the day after each exercise session

Interventionpercentage (Median)
Control32
Basal Insulin Reduction35
Glucose Tabs36
G-Pen Mini™ (Glucagon Injection)33

CGM Metrics During Late Recovery - Mean Glucose

Comparison of mean glucose from CGM between the exercise strategies. (NCT02660242)
Timeframe: 90 min after the standard meal until 1200 noon the day after each exercise session

Interventionmg/dL (Median)
Control129
Basal Insulin Reduction139
Glucose Tabs130
G-Pen Mini™ (Glucagon Injection)147

CGM Metrics During Late Recovery - Peak Glucose

Comparison of peak glucose from CGM between the exercise strategies. (NCT02660242)
Timeframe: 90 min after the standard meal until 1200 noon the day after each exercise session

Interventionmg/dL (Median)
Control241
Basal Insulin Reduction239
Glucose Tabs267
G-Pen Mini™ (Glucagon Injection)269

CGM Metrics During Late Recovery - Time < 54 mg/dL

Comparison of percentage of time < 54 mg/dL from CGM between the exercise strategies. (NCT02660242)
Timeframe: 90 min after the standard meal until 1200 noon the day after each exercise session

Interventionpercentage (Mean)
Control3
Basal Insulin Reduction3
Glucose Tabs3
G-Pen Mini™ (Glucagon Injection)2

CGM Metrics During Late Recovery - Time < 70 mg/dL

Comparison of percentage of time < 70 mg/dL from CGM between the exercise strategies. (NCT02660242)
Timeframe: 90 min after the standard meal until 1200 noon the day after each exercise session

Interventionpercentage (Mean)
Control10
Basal Insulin Reduction8
Glucose Tabs8
G-Pen Mini™ (Glucagon Injection)6

CGM Metrics During Late Recovery - Time > 180 mg/dL

Comparison of percentage of time > 180 mg/dL from CGM between the exercise strategies. (NCT02660242)
Timeframe: 90 min after the standard meal until 1200 noon the day after each exercise session

Interventionpercentage (Mean)
Control16
Basal Insulin Reduction21
Glucose Tabs23
G-Pen Mini™ (Glucagon Injection)26

CGM Metrics During Late Recovery - Time > 250 mg/dL

Comparison of percentage of time > 250 mg/dL from CGM between the exercise strategies. (NCT02660242)
Timeframe: 90 min after the standard meal until 1200 noon the day after each exercise session

Interventionpercentage (Mean)
Control1
Basal Insulin Reduction4
Glucose Tabs9
G-Pen Mini™ (Glucagon Injection)5

CGM Metrics During Late Recovery - Time in Range (70-180 mg/dL)

Comparison of percentage of time in range (70-180 mg/dL) from CGM between the exercise strategies. (NCT02660242)
Timeframe: 90 min after the standard meal until 1200 noon the day after each exercise session

Interventionpercentage (Mean)
Control73
Basal Insulin Reduction71
Glucose Tabs69
G-Pen Mini™ (Glucagon Injection)67

Continuous Glucose Monitor (CGM) Metrics During Late Recovery - Nadir Glucose

Comparison of nadir glucose from CGM between the exercise strategies. (NCT02660242)
Timeframe: 90 min after the standard meal until 1200 noon the day after each exercise session

Interventionmg/dL (Median)
Control45
Basal Insulin Reduction44
Glucose Tabs49
G-Pen Mini™ (Glucagon Injection)51

Number of Participants With Hyperglycemia (≥250 mg/dL) During Exercise and Early Recovery

Comparison of occurrence of hyperglycemia (≥250 mg/dL from blood glucose) during exercise and early recovery between each exercise strategy. (NCT02660242)
Timeframe: 0 to 75 minutes following exercise initiation

InterventionParticipants (Count of Participants)
Control0
Basal Insulin Reduction0
Glucose Tabs5
G-Pen Mini™ (Glucagon Injection)1

Number of Participants With Hypoglycemia (<70 mg/dL) During Exercise and Early Recovery

Comparison of occurrence of hypoglycemia (<70 mg/dL from blood glucose) during exercise and early recovery between each exercise strategy. (NCT02660242)
Timeframe: 0 to 75 minutes following exercise initiation

InterventionParticipants (Count of Participants)
Control6
Basal Insulin Reduction5
Glucose Tabs0
G-Pen Mini™ (Glucagon Injection)0

Glycemic Response During Exercise and Early Recovery

Comparison of glycemic response (from blood glucose) during exercise and early recovery between each exercise strategy. (NCT02660242)
Timeframe: 0 to 75 minutes following exercise initiation (0, 5, 10, 15, 25, 35, 45, 50, 55, 60, 75 min)

,,,
Interventionmg/dL (Mean)
Plasma Glucose Concentration (End of Exercise)Plasma Glucose Concentration (End Early Recovery)
Basal Insulin Reduction8592
Control8690
G-Pen Mini™ (Glucagon Injection)161163
Glucose Tabs174222

CGM Coefficient of Variation

Coefficient of Variation from CGM data computed over entire 3 weeks of treatment period (NCT02411578)
Timeframe: 3 weeks

Interventionpercentage coefficient of variation (Median)
G-Pen Mini™ (Glucagon Injection)35
Glucose Tabs36

CGM Maximum Glucose, Event Level

Maximum glucose from CGM data, following each hypoglycemic event with starting BG 50-69 mg/dL, during first 2 hours after start of hypoglycemic event (NCT02411578)
Timeframe: 120 Minutes

Interventionmg/dL (Median)
G-Pen Mini™ (Glucagon Injection)122
Glucose Tabs139

CGM Maximum Glucose, Event Level

Maximum glucose from CGM data, following each hypoglycemic event with starting BG 50-69 mg/dL, during first hour after start of hypoglycemic event (NCT02411578)
Timeframe: 60 Minutes

Interventionmg/dL (Median)
G-Pen Mini™ (Glucagon Injection)102
Glucose Tabs116

CGM Mean Glucose

Median (IQR) reported for mean glucose from CGM data computed over entire 3 weeks of treatment period (NCT02411578)
Timeframe: 3 weeks

Interventionmg/dL (Median)
G-Pen Mini™ (Glucagon Injection)143
Glucose Tabs149

CGM Mean Glucose, Event Level

Median (IQR) reported for mean glucose from CGM data, following each hypoglycemic event with starting BG 50-69 mg/dL, during first 2 hours after start of hypoglycemic event (NCT02411578)
Timeframe: 120 Minutes

Interventionmg/dL (Median)
G-Pen Mini™ (Glucagon Injection)95
Glucose Tabs108

CGM Mean Glucose, Event Level

Median (IQR) reported for mean glucose from CGM data, following each hypoglycemic event with starting BG 50-69 mg/dL, during first hour after start of hypoglycemic event (NCT02411578)
Timeframe: 60 Minutes

Interventionmg/dL (Median)
G-Pen Mini™ (Glucagon Injection)79
Glucose Tabs87

CGM Minimum Glucose, Event Level

Minimum glucose from CGM data, following each hypoglycemic event with starting BG 50-69 mg/dL, during first 2 hours after start of hypoglycemic event (NCT02411578)
Timeframe: 120 Minutes

Interventionmg/dL (Median)
G-Pen Mini™ (Glucagon Injection)57
Glucose Tabs56

CGM Time Below 70

Percentage of time <70 mg/dL from CGM data computed over entire 3 weeks of treatment period (NCT02411578)
Timeframe: 3 weeks

Interventionpercentage of time (Median)
G-Pen Mini™ (Glucagon Injection)5
Glucose Tabs4

CGM Time Below 70 mg/dL

Percentage of time <70 mg/dL from CGM data, following each hypoglycemic event with starting BG 50-69 mg/dL, during first 2 hours after start of hypoglycemic event (NCT02411578)
Timeframe: 120 Minutes

Interventionpercentage of time (Median)
G-Pen Mini™ (Glucagon Injection)20
Glucose Tabs19

CGM Time Below 70 mg/dL, Event Level

Percentage of time <70 mg/dL from CGM data, following each hypoglycemic event with starting BG 50-69 mg/dL, during first hour after start of hypoglycemic event (NCT02411578)
Timeframe: 60 Minutes

Interventionpercentage of time (Median)
G-Pen Mini™ (Glucagon Injection)35
Glucose Tabs33

CGM Time in Range

Percentage of time 70-180 mg/dL from CGM data computed over entire 3 weeks of treatment period (NCT02411578)
Timeframe: 3 weeks

Interventionpercentage of time (Median)
G-Pen Mini™ (Glucagon Injection)71
Glucose Tabs71

CGM Time in Range, Event Level

Percentage of time 70-180 mg/dL from CGM data, following each hypoglycemic event with starting BG 50-69 mg/dL, during first 2 hours after start of hypoglycemic event (NCT02411578)
Timeframe: 120 Minutes

Interventionpercentage of time (Median)
G-Pen Mini™ (Glucagon Injection)79
Glucose Tabs79

CGM Time in Range, Event Level

Percentage of time 70-180 mg/dL from CGM data, following each hypoglycemic event with starting BG 50-69 mg/dL, during first hour after start of hypoglycemic event (NCT02411578)
Timeframe: 60 Minutes

Interventionpercentage of time (Median)
G-Pen Mini™ (Glucagon Injection)62
Glucose Tabs67

Clinical Grading - Initial and 15-min Treatment Correct

2 graders, blinded to treatment arm, independently graded each hypoglycemic event as a clinical failure or success based on all available BG concentrations within 1 hour of initial treatment. All BG values, along with corresponding time elapsed since treatment, were reviewed to determine whether the response would be considered a treatment success, in a clinical setting. There were no specific cut points; rather than basing the success criteria on whether the BG was above specific cutpoints by specific times, the grader decided whether the event would be considered a success in a clinical setting (i.e. if the BG increased after treatment and reached and maintained a satisfactory level after the treatment). The graders to achieve a consensus grading adjudicated discordant gradings (6% of events). The number of events graded as a treatment success were reported out of the total number of hypoglycemic events, for each treatment arm. (NCT02411578)
Timeframe: 60 minutes

InterventionHypoglycemic Events (Count of Units)
G-Pen Mini™ (Glucagon Injection)66
Glucose Tabs63

Clinical Grading - Initial Treatment Correct

2 graders, blinded to treatment arm, independently graded each hypoglycemic event as a clinical failure or success based on all available BG concentrations within 1 hour of initial treatment. All BG values, along with corresponding time elapsed since treatment, were reviewed to determine whether the response would be considered a treatment success, in a clinical setting. There were no specific cut points; rather than basing the success criteria on whether the BG was above specific cutpoints by specific times, the grader decided whether the event would be considered a success in a clinical setting (i.e. if the BG increased after treatment and reached and maintained a satisfactory level after the treatment). The graders to achieve a consensus grading adjudicated discordant gradings (6% of events). The number of events graded as a treatment success were reported out of the total number of hypoglycemic events, for each treatment arm. (NCT02411578)
Timeframe: 60 minutes

InterventionHypoglycemic Events (Count of Units)
G-Pen Mini™ (Glucagon Injection)84
Glucose Tabs88

Clinical Grading - Limited to Events in Primary Analysis

2 graders, blinded to treatment arm, independently graded each hypoglycemic event as a clinical failure or success based on all available BG concentrations within 1 hour of initial treatment. All BG values, along with corresponding time elapsed since treatment, were reviewed to determine whether the response would be considered a treatment success, in a clinical setting. There were no specific cut points; rather than basing the success criteria on whether the BG was above specific cutpoints by specific times, the grader decided whether the event would be considered a success in a clinical setting (i.e. if the BG increased after treatment and reached and maintained a satisfactory level after the treatment). The graders to achieve a consensus grading adjudicated discordant gradings (6% of events). The number of events graded as a treatment success were reported out of the total number of hypoglycemic events, for each treatment arm. (NCT02411578)
Timeframe: 60 minutes

InterventionHypoglycemic Events (Count of Units)
G-Pen Mini™ (Glucagon Injection)57
Glucose Tabs54

Continuous Glucose Monitor (CGM) Minimum Glucose, Event Level

Minimum glucose from CGM data, following each hypoglycemic event with starting BG 50-69 mg/dL, during first hour after start of hypoglycemic event (NCT02411578)
Timeframe: 60 Minutes

Interventionmg/dL (Median)
G-Pen Mini™ (Glucagon Injection)59
Glucose Tabs56

Number of Hypoglycemic Events ≥50 mg/dl 15 Minutes AND ≥ 70 mg/dl 30 Minutes After Initial Treatment

(NCT02411578)
Timeframe: 30 minutes

InterventionHypoglycemic Events (Count of Units)
G-Pen Mini™ (Glucagon Injection)58
Glucose Tabs53

Trials

7 trials available for terbutaline and Diabetes Mellitus, Type 1

ArticleYear
Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes.
    Diabetes care, 2008, Volume: 31, Issue:12

    Topics: Adrenergic beta-Agonists; Adult; Diabetes Mellitus, Type 1; Female; Humans; Hypoglycemia; Male; Terb

2008
Preventing post-exercise nocturnal hypoglycemia in children with type 1 diabetes.
    The Journal of pediatrics, 2010, Volume: 157, Issue:5

    Topics: Adolescent; Diabetes Mellitus, Type 1; Exercise; Female; Humans; Hypoglycemia; Insulin; Male; Terbut

2010
Preventing post-exercise nocturnal hypoglycemia in children with type 1 diabetes.
    The Journal of pediatrics, 2010, Volume: 157, Issue:5

    Topics: Adolescent; Diabetes Mellitus, Type 1; Exercise; Female; Humans; Hypoglycemia; Insulin; Male; Terbut

2010
Preventing post-exercise nocturnal hypoglycemia in children with type 1 diabetes.
    The Journal of pediatrics, 2010, Volume: 157, Issue:5

    Topics: Adolescent; Diabetes Mellitus, Type 1; Exercise; Female; Humans; Hypoglycemia; Insulin; Male; Terbut

2010
Preventing post-exercise nocturnal hypoglycemia in children with type 1 diabetes.
    The Journal of pediatrics, 2010, Volume: 157, Issue:5

    Topics: Adolescent; Diabetes Mellitus, Type 1; Exercise; Female; Humans; Hypoglycemia; Insulin; Male; Terbut

2010
Modified release terbutaline (SKP1052) for hypoglycaemia prevention: a proof-of-concept study in people with type 1 diabetes mellitus.
    Diabetes, obesity & metabolism, 2012, Volume: 14, Issue:12

    Topics: Adolescent; Adult; Blood Glucose; Cross-Over Studies; Delayed-Action Preparations; Diabetes Mellitus

2012
Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:6

    Topics: Acarbose; Adult; Blood Glucose; Blood Pressure; Circadian Rhythm; Diabetes Mellitus, Type 1; Female;

2006
Glycemic actions of alanine and terbutaline in IDDM.
    Diabetes care, 1993, Volume: 16, Issue:8

    Topics: Administration, Oral; Alanine; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 1; Epinephrine; Fat

1993
Alanine and terbutaline in treatment of hypoglycemia in IDDM.
    Diabetes care, 1993, Volume: 16, Issue:8

    Topics: 3-Hydroxybutyric Acid; Administration, Oral; Alanine; Blood Glucose; C-Peptide; Diabetes Mellitus, T

1993
Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDM.
    Diabetes care, 1997, Volume: 20, Issue:8

    Topics: Adrenergic beta-Agonists; Adult; Alanine; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 1

1997

Other Studies

5 other studies available for terbutaline and Diabetes Mellitus, Type 1

ArticleYear
Defective activation of skeletal muscle and adipose tissue lipolysis in type 1 diabetes mellitus during hypoglycemia.
    The Journal of clinical endocrinology and metabolism, 2003, Volume: 88, Issue:4

    Topics: Adipose Tissue; Adrenergic beta-Agonists; Adult; Blood Glucose; Diabetes Mellitus, Type 1; Epinephri

2003
Beta-sympathomimetic therapy of premature labor.
    Diabetes care, 1996, Volume: 19, Issue:8

    Topics: Adult; Diabetes Mellitus, Type 1; Female; Humans; Infant, Newborn; Insulin; Magnesium Sulfate; Male;

1996
Microdialysis for the assessment of catecholamine-induced lipolysis in adipose and skeletal muscle tissue.
    Advances in pharmacology (San Diego, Calif.), 1998, Volume: 42

    Topics: Adipose Tissue; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Catecholamines; Diabetes Mell

1998
Diabetic ketoacidosis and insulin resistance with subcutaneous terbutaline infusion: a case report.
    American journal of obstetrics and gynecology, 1990, Volume: 163, Issue:2

    Topics: Adult; Diabetes Mellitus, Type 1; Diabetic Ketoacidosis; Female; Humans; Infusions, Parenteral; Inje

1990
Opposite effects of insulin and catecholamines on LDL-receptor activity in human mononuclear leukocytes.
    Diabetes, 1988, Volume: 37, Issue:10

    Topics: Catecholamines; Diabetes Mellitus, Type 1; Epinephrine; Humans; In Vitro Techniques; Insulin; Isopro

1988